NSCLC

This study aims to find out if it's safe and effective for people with a specific type of advanced lung cancer (EGFR-positive NSCLC) to continue taking their daily oral medication, osimertinib, while also receiving radiation therapy. It involves 42 participants who need radiation…

This study is testing whether adding very high doses of vitamin C (given through an IV) to standard chemotherapy and radiation treatment helps people with non-small cell lung cancer. All 43 participants will receive the vitamin C infusion along with their usual cancer therapy. Re…

This study is testing how well the drug brigatinib works for people with advanced non-small cell lung cancer that has a specific genetic change (ALK+). Researchers will also explore if simple blood tests (liquid biopsies) can help track how the cancer responds to treatment over t…

This study is testing whether adding a new immunotherapy drug called cadonilimab (AK104) to standard chemotherapy and radiation can better control advanced, inoperable lung cancer. It involves 41 patients who will receive the drug before, during, and for a year after their standa…

This study provides continued access to the lung cancer drug lorlatinib for patients who are already benefiting from it in previous Pfizer trials. It allows 76 participants with specific genetic types of non-small cell lung cancer (ALK-positive or ROS1-positive) to keep receiving…

This study is testing whether a new drug called AK112, which targets two cancer pathways at once, works better when combined with standard chemotherapy for advanced non-small cell lung cancer (NSCLC). It involved 265 adults with stage IIIB/C or IV NSCLC to see if the combination …

This study tests whether adding an immunotherapy drug (atezolizumab) to standard chemotherapy after lung cancer surgery can better prevent the cancer from returning. It focuses on patients who have signs of remaining cancer cells in their blood after surgery, which indicates high…

This study is testing an oral medication called BDTX-1535 for adults with advanced non-small cell lung cancer or glioblastoma (a type of brain tumor) that have specific genetic changes. The goal is to find the safest and most effective dose and see if the drug can shrink tumors, …

This study is testing two different immunotherapy drug combinations, given before and after standard chemoradiation, for people with stage III non-small cell lung cancer that cannot be removed by surgery. The goal is to see which combination is more promising for keeping the canc…

This study is testing a drug called Lazertinib as the first treatment for people with advanced non-small cell lung cancer (NSCLC) that has specific genetic changes (EGFR mutations). The main goals are to see how well the drug controls the cancer, how safe it is, and to understand…

This study is testing whether adding an immunotherapy drug called durvalumab to a precise form of radiation therapy (SBRT) works better than radiation alone for early-stage lung cancer. It is for patients with a higher risk of their cancer returning who are not candidates for sur…

This study provides continued access to crizotinib treatment for people with certain cancers who were already benefiting from the medication in previous Pfizer trials that are closing. It allows 27 eligible participants to keep receiving their treatment while researchers continue…

This early-stage study is testing a drug called furmonertinib for people with advanced non-small cell lung cancer that has a specific genetic mutation called EGFR exon 20 insertion. The trial will enroll 30 people to see if the drug is safe and can help shrink or control their tu…

This early-phase study is testing an experimental oral medication called MRT-2359 in people with advanced cancers that have run out of standard treatment options. The trial focuses on several types of solid tumors and lymphoma, particularly those driven by specific genes called L…

This study is testing whether adding an immunotherapy drug called serplulimab to standard chemotherapy before surgery helps people with operable non-small cell lung cancer. The goal is to see if this combination treatment can better shrink tumors before removal, lower the chance …

This is a first-in-human study to find a safe dose and see if a new drug called CLN-619 can help control advanced solid tumors. It will test CLN-619 by itself and combined with other approved cancer drugs. The study is for adults with cancers like advanced lung, cervical, or endo…

This study is testing an experimental drug called JAB-21822 (glecirasib) for people with advanced cancers that have a specific genetic change called KRAS G12C mutation. The trial aims to find the safest and most effective dose while checking if the drug can shrink tumors. It incl…

This study aims to see if the drug brigatinib works better than other similar drugs for people with a specific type of advanced lung cancer (ALK-positive NSCLC). It will involve about 118 adults who have not yet received treatment for their advanced cancer. Researchers will close…

This study is testing whether combining a drug called durvalumab (an immunotherapy) with radiation therapy can help control locally advanced non-small cell lung cancer. It is for patients who are not eligible for the standard treatment of chemotherapy followed by radiation, often…

This study is testing whether adding a drug called S-1 to a standard lung cancer medication (osimertinib) can help control cancer that has started growing again. It is for 30 adults with a specific type of advanced lung cancer (EGFR mutant NSCLC) that has become resistant to osim…

This early-stage trial is testing the safety and best dose of a new two-drug combination for people with advanced solid tumors that have stopped responding to standard treatments. The study is focusing on specific cancers, including certain types of lung, ovarian, and pancreatic …

This large, global study is comparing a new three-drug combination to the current standard treatment for adults with advanced non-small cell lung cancer (NSCLC) that has spread and lacks certain genetic markers. The goal is to see if the new combination, which includes an experim…

This early-stage trial is testing the safety and finding the right dose of a two-drug combination (naptumomab estafenatox and durvalumab) for people with advanced or metastatic solid tumors. It will enroll about 120 adults with one of many eligible cancer types, including breast,…

This study aimed to see if a new drug called poziotinib works better than standard chemotherapy (docetaxel) for people with advanced non-small cell lung cancer that has a specific HER2 gene mutation and has worsened after prior treatments. It directly compared how long each treat…

This study is testing whether new drug treatments given before surgery can shrink lung tumors and prevent cancer from coming back. It's for people with early-stage non-small cell lung cancer that can be surgically removed. Researchers are looking at how patients' specific cancer …

This study is testing an oral drug called furmonertinib for adults with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion) and has worsened after standard chemotherapy. The main goal is to see if the drug can shrink tumors and control …

This study is testing whether using a precise, high-dose radiation treatment on a few new or growing tumors can help people with advanced lung or breast cancer stay on their current medications longer. It aims to see if this approach can delay the cancer from getting worse. The t…

This study is testing the best way to use the drug osimertinib for advanced lung cancer with a specific genetic change (EGFR mutation). It compares starting osimertinib right away versus starting another drug first and switching to osimertinib later, guided by a blood test that l…

This study aims to see if a simple blood test can predict whether lung cancer will return after surgery. Researchers will test blood from patients before and after their lung cancer operation, looking for tiny DNA fragments from the tumor. The goal is to see if the test results o…

This is a remote study aiming to understand why some young adults get lung cancer. Researchers will ask participants about their lifestyle, environment, and genetics through online surveys and optional blood donation. The goal is to gather information that may help identify risk …

This study aims to understand how well the drug alectinib works for people with a specific type of advanced lung cancer (ALK-positive NSCLC) in real-world settings, outside of a controlled clinical trial. It will follow 800 patients already receiving this treatment as part of the…